Sort   by:  
 Page size 
UnknownProteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).

Introduction

Disruptions of proteasome and autophagy systems are central events in amyotrophic lateral sclerosis (ALS) and support the urgent need to find therapeutic compounds targeting these processes. The heat shock protein B8 (HSPB8) recognises and promotes the autophagy-mediated removal...
S-EPMC6549675 | biostudies-literature
UnknownCOVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM.

Background

There is no data regarding COVID-19 in Multiple Sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients in Latin America.

Objective

The objective of this study was to describe the clinical characteristics and outcomes of patients included in RELACOEM, a L...
S-EPMC7937038 | biostudies-literature
Sort   by:  
 Page size